Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2014, Vol. 19 ›› Issue (1): 90-95.
Previous Articles Next Articles
YANG Meng1,2, ZUO Xiao-cong1,2,WANG Jiang-lin1,2,CHEN Qing-Jie1,2
Received:
2013-01-04
Revised:
2014-01-09
Online:
2014-01-27
Published:
2014-02-12
CLC Number:
YANG Meng, ZUO Xiao-cong,WANG Jiang-lin,CHEN Qing-Jie. Advance in study on tacrolimus pharmacodynamics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 90-95.
[1] Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice[J]. Clin Ther, 2002, 24(3):330-350. [2] Dambrin C, Klupp J, Morris RE.Pharmacodynamics of immunosuppressive drugs[J].Curr Opin Immunol , 2000, 12(5):557-562. [3] El-Safa EA, Fredericks S, MacPhee I,et al. Paradoxical response to tacrolimus assessed by interleukin-2 gene expression [J]. Transplant Proc,2006,38(10):3327-3330. [4] Barten MJ, Tarnok A, Garbade J, et al. Pharmacodynamics of T-cell function for monitoring immunosuppression[J]. Cell Prolif,2007,40(1):50-63. [5] Ke H, Huai Q. Structures of calcineurin and its complexes with immunophilins-immunosuppressants[J]. Biochem Biophys Res Commun, 2003, 311(4):1095-1102. [6] Migita K, Eguchi K. FK506-mediated T-cell apoptosis induction[J]. Transplant Proc,2001 ,33(3):2292-2293. [7] Choi SJ, You HS, Chung SY. Tacrolimus-Induced Apoptotic Signal Transduction Pathway[J]. Transplant Proc, 2008, 40 (8):2734-2736. [8] Satoshi M, Futoshi S, Kenji T, et al. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation[J].EMBO, 2000, 1(5):428-434. [9] 何懿,李民,刘占国,等.他克莫司对全血细胞因子分泌的影响[J].南方医科大学学报,2010,30(2):249-251. [10] Liu ZG, Yuan XP, Luo YW, et al. Evaluating the effects of immunosuppressants on human immunity using cytokine profiles of whole blood[J].Cytokine, 2009, 45 (2):141-147. [11] Wei HY, Pan W, Qiu N, et al. High concentration of tacrolimus inhibits proliferation and osteoblastic differentiation of human mesenchymal stem cells[J].Chin J Pharmacol Toxicol, 2011, 25(3): 223-228. [12] Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients[J]. Clin Transplant, 1999, 13(5): 400-409. [13] Jamie LM , Ericson SG. Cyclosporin A and Tacrolimus (FK506) differentially alter T-cell receptor expression in vivo[J].Immunopharm Immunot, 2007,29(1):105-118. [14] 白杨娟,王兰兰,蔡蓓,等.他克莫司与环孢菌素A对肝移植受者CD4/CD8T淋巴细胞亚群及共刺激分子的调节作用[J].细胞与分子免疫学杂志,2008,24(10):989-992. [15] Wu CS, Lan CC, Kuo HY,et al. Differential regulation of nuclear factor-kappa B subunits on epidermal keratinocytes by ultraviolet B and tacrolimus[J]. Kaohsiung J Med Sci, 2012, 28(11):577-585. [16] 孙君重,肖文华,于力.CD4+ T淋巴细胞功能研究新进展[J].中国实验血液学杂志,2010,18(2):544-548. [17] 郭业磊,陈钰.CD8+ T调节细胞的研究进展[J]. 细胞与分子免疫学杂志,2009,25(8):762-763. [18] 李佳,白杨娟,王兰兰,等.FK506对肝移植受者T细胞亚群上CD152和PD-1的调节研究[J].细胞与分子免疫学杂志,2008,24(1):54-57. [19] Claudia S, Martin Z, Stefan M, et al. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-Treated kidney transplant recipients[J].Transplantation, 2010, 89 (11):1417-1423. [20] Cheung CY, Chan HW, Liu YL, et al. Long-term graft function with tacrolimus and cyclosporine in renal transplantation: Paired kidney analysis[J].Nephrology , 2009,14(8):758-763. [21] Mizuiri S, Iwamoto M, Miyagi M, et al. Activation of nuclear factor-kappa B and macrophage invasion in cyclosporin A and tacrolimus-treated renal transplants[J]. Clin Transplant, 2004, 18(1): 14-20. [22] Hymes LC, Warshaw BL. Tacrolimus rescue therapy for children with acute renal transplant rejection[J]. Pediatr Nephrol, 2001, 16(12):990-992. [23] Demirci MS, Toz H, Ylmaz F, et al. Risk factors and consequences of post-transplant diabetes mellitus[J]. Clin Transplant, 2010,24(5): 170-177. [24] Ochiai T, Nakajima K, Nagata M, et al. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allo-transplantation in rats[J]. Transplantation, 1987, 44(6): 734 -738. [25] Moriuchi H, Kamohara Y, Eguchi S,et al. Diverse effects of FK506 on the apoptosis of hepatocytes and infiltrating lymphocytes in an allografted rat liver[J]. J Surg Res, 2011,167(1):131-139. [26] 魏思东,龚建平,李金政,等. 他克莫司通过抑制GITRL减轻大鼠肝移植排斥反应的研究[J].南方医科大学学报,2011,31(9):1480-1483. [27] Jiang H, Yang XF, Wynn C, et al. IL-10: a tacrolimus-specific cytotoxic mediator in ongoing allograft rejection[J]. Transplant Proc, 2001, 33(1/2):510-513. [28] Zhu L, Hua ZH, Song HT. Pharmacogenomics and personalized medicine of tacrolimus[J].Chin J Clin Pharmacol Ther,2011, 16(6): 710-750. [29] Pech T, Fujishiro J, Finger T,et al. Effects of immunesuppressive therapy after experimental small bowel transplantation in rats[J]. Transpl Immunol, 2011, 25(2/3) : 112-118. [30] Qi XM , Wu YG, Liang C,et al. FK506 ameliorates renal injury in early experimental diabetic rats induced by streptozotocin [J]. Int Immunopharmacol, 2011,11(10):1613-1619. [31] Justo P, Lorz C, Sanz A , et al. Intracellular mechanisms of cyclosporine A-induced tubular cell apoptosis[J].Am Soc Nephrol, 2003, 14(12):3072-3080. [32] Yang CW, Faulkner GR, Wahba IM, et al. Expression of apoptosis related genes in chronic cyclosporine nephrotoxicity in mice[J]. Am J Transplant, 2002,2(5) :391- 399. [33] Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine associa ted interstitialfi brosis[J]. Kidney Int,1998, 53(4) :897- 908. [34] Shihab FS, Andoh TF, Tanner AM, et al. Expression of apoptosis regulatory genes in chronic cyclospori ne nephrotoxicity favors apoptosis[J]. Kidney Int, 1999,56(6):2147-2159. [35] Ewout JH, Walsh SB, McCormick JA,et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension[J]. Nat Med,2012, 17(10): 1304-1309. [36] Chiasson VL, Talreja D, Yong KJ, et al. FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension[J].Hypertension, 2011,57(6):1167-1175. [37] Rauch MC, San Martín A, Ojeda D, et al. Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects[J]. Transpl Immunol,2009, 22(1/2): 72-81. [38] Khoury N, Kriaa F, Hiesse C,et al. Posttransplant diabetes mellitus in kidney transplant recipients under tacrolimus immunosuppression[J].Transplant Pro,2000, 32(8):2763-2764. [39] Chiasson VL, Jones KA, Kopriva SE,et al. Endothelial cell trans-forming growth factor-β receptor activation causes tacrolimus-induced renal arteriolar hyalinosis[J].Kidney Int,2012,82(8):1-10. [40] De Rycke A, Dierickx D, Kuypers DR. Tacrolimus-induced neutropenia in renal transplant recipients[J]. Clin J Am Soc Nephrol,2011,6(3): 690 - 694. [41] 陈斌,马爱民,林建群.他克莫司的不良反应[J].海峡药学,2007,19(10):130-131. [42] Ruth AL ,Steven G. Current trends in immunosuppressive therapies for renal transplant recipients [J]. Am J Health-Syst Pharm, 2012,69 (15):1961-1975. [43] 龚丽娴,袁进.他克莫司致高钾血症1例[J].医药导报,2012,6(31):705. |
[1] | WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033. |
[2] | LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774. |
[3] | CHEN Yining, XIAO Yun, HAN Xiaoyu, HUANG Lulu, MA Jingsheng, XIONG Hanbin, FU Yu, WANG Baolin, GUO Xiaohui, ZHONG Lin, AO Jiangen, HE Jiake. Diagnosis and individualized drug therapy for the rejection with hyperglycemia after liver Transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 550-555. |
[4] | WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213. |
[5] | MA Yitong, MA Jianhong, GAO Yating, LIU Chang. Pathogenic mechanism and research progress of adipocytokines in endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1315-1320. |
[6] | HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50. |
[7] | WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997. |
[8] | GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing. Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833. |
[9] | DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake. Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651. |
[10] | GAO Jiarong, SHI Miaomiao, CHEN Hao, JIANG Hui, QIN Xiujuan. Effect of Qiteng Xiaozhuo granule mediating miR-339-5p on inflammatory indexes in rats with chronic glomerulonephritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 457-465. |
[11] | ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212. |
[12] | XU Liying, ZHANG Gaosong, HUANG Xiaomin, HUANG Jihan, WANG Shuhua. Clinical efficacy and modeling evaluation of He-wei-zhi-xie capsules in treating diarrhea patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 47-55. |
[13] | WU Yi, FANG Fang, CHEN Ying, Fan Junwei. Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639. |
[14] | HE Xiujuan, MA Huike, LIU Qingwu, CHEN Jia, LIN Yan, LI Ping. Research progress of cytokines in wound healing [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 579-585. |
[15] | JIAO Zheng, LI Xingang, SHANG Dewei, DONG Jing, ZUO Xiaocong, CHEN Bing, LIU Jianmin, PAN Yan, ZHOU Tianyan, ZHANG Jing, LIU Dongyang, LI Lujin, FANG Yi, MA Guangli, DING Junjie, ZHAO Wei, CHEN Rui, XIANG Xiaoqiang, WANG Yuzhu, GAO Jianjun, XIE Haitang, HU Pei, ZHENG Qingshan. Model informed precision dosing: China expert consensus report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1215-1228. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 760
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 262
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||